Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results

Francesca De Felice; Daniela Musio; Giovanni Luca Gravina; Francesco Marampon; Vincenzo Tombolini

doi:10.18632/oncotarget.11374

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results

Francesca De Felice _, Daniela Musio, Giovanni Luca Gravina, Francesco Marampon and Vincenzo Tombolini

PDF | HTML | How to cite

Oncotarget. 2016; 7:80077-80082. https://doi.org/10.18632/oncotarget.11374

Metrics: PDF 1597 views | HTML 2293 views | ?

Abstract

Francesca De Felice1, Daniela Musio1, Giovanni Luca Gravina2, Francesco Marampon2 and Vincenzo Tombolini1,3

1 Department of Radiotherapy, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy

2 Department of Biotechnological and Applied Clinical Sciences, Laboratory of Radiobiology, University of L’Aquila, L’Aquila, Italy

3 Spencer-Lorillard Foundation, Viale Regina Elena, Rome, Italy

Correspondence to:

Francesca De Felice, email:

Keywords: radiotherapy; stage I seminoma; surveillance; chemotherapy; orchiectomy

Received: May 22, 2016 Accepted: August 13, 2016 Published: August 18, 2016

Abstract

Aim: To report long term oncologic outcomes after adjuvant radiotherapy (RT) for stage I seminoma.

Method: We reviewed the complete data set for all patients treated at our institute between 1988 and 2005 for stage I seminoma with adjuvant RT after radical orchiectomy .

Results: A total of 85 patients were included. The median follow-up was 15 years. The 20-year overall survival (OS) and relapse free survival (RFS) were 92% and 96.3%, respectively. No severe acute and late complications were recorded. Overall 5.9% of patients had a second unrelated malignancy.

Conclusion: Adjuvant RT is an efficacious and safe treatment in stage I seminoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11374

Publication Alerts

Post-Publication Promotion

Publication Discount

Clinical Research Papers:

Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results

Abstract